New retrospective data shows half of rrp patients treated with ino-3107 achieved a complete response when evaluated 2 and 3 years following initial phase 1/2 trial

Data from a retrospective trial evaluating the longer-term benefit of ino-3107 to patients with recurrent respiratory papillomatosis (rrp) involved in a phase 1/2 trial showed the number of patients who met the criteria for a complete response (cr) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospective trial (rrp-002) maintained or enhanced their original overall response rate (orr) reported in the phase 1/2 trial (rrp-001) by the end of year 2; 86% of patients maintained or enhanced orr into year 3 new durability data will help inform re-dosing strategy focused on long-term elimination or reduction in the need for surgery to treat rrp disease inovio plans to present data at future scientific conferences and submit for publication in peer-reviewed journals plymouth meeting, pa. , dec. 3, 2024 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced data from a retrospective trial showing that the number of rrp patients meeting the criteria for a complete response increased to 50% by the end of the second year following initial treatment with ino-3107 in a previously reported phase 1/2 52-week trial where the complete response rate was 28%.
INO Ratings Summary
INO Quant Ranking